209 related articles for article (PubMed ID: 36581707)
21. The exploitation of enzyme-based cancer immunotherapy.
Chandan G; Saini AK; Kumari R; Chakrabarti S; Mittal A; Sharma AK; Saini RV
Hum Cell; 2023 Jan; 36(1):98-120. PubMed ID: 36334180
[TBL] [Abstract][Full Text] [Related]
22. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
24. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
25. AMPK-a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment?
Wang N; Wang B; Maswikiti EP; Yu Y; Song K; Ma C; Han X; Ma H; Deng X; Yu R; Chen H
Cell Death Discov; 2024 May; 10(1):237. PubMed ID: 38762523
[TBL] [Abstract][Full Text] [Related]
26. Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer.
Pogoda K; Pyszniak M; Rybojad P; Tabarkiewicz J
Oncol Lett; 2016 Dec; 12(6):4785-4794. PubMed ID: 28101225
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y; Tang F; Wei YQ; Wei XW
J Hematol Oncol; 2022 May; 15(1):61. PubMed ID: 35585567
[TBL] [Abstract][Full Text] [Related]
28. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
29. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer.
Morse MA; Hall JR; Plate JM
Expert Opin Biol Ther; 2009 Mar; 9(3):331-9. PubMed ID: 19216622
[TBL] [Abstract][Full Text] [Related]
30. A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment.
Kuo CL; Chou HY; Lien HW; Yeh CA; Wang JR; Chen CH; Fan CC; Hsu CP; Kao TY; Ko TM; Lee AY
Cancer Immunol Immunother; 2023 Feb; 72(2):351-369. PubMed ID: 35895109
[TBL] [Abstract][Full Text] [Related]
31. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
Pi YN; Qi WC; Xia BR; Lou G; Jin WL
Front Immunol; 2021; 12():697083. PubMed ID: 34295338
[TBL] [Abstract][Full Text] [Related]
32. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
34. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
35. Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity.
Singh A; Anang V; Kumari K; Kottarath SK; Verma C
Prog Mol Biol Transl Sci; 2023; 194():269-310. PubMed ID: 36631195
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
37. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis.
Niesel K; Schulz M; Anthes J; Alekseeva T; Macas J; Salamero-Boix A; Möckl A; Oberwahrenbrock T; Lolies M; Stein S; Plate KH; Reiss Y; Rödel F; Sevenich L
EMBO Mol Med; 2021 May; 13(5):e13412. PubMed ID: 33755340
[TBL] [Abstract][Full Text] [Related]
38. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment.
Sun K; Yu J; Hu J; Chen J; Song J; Chen Z; Cai Z; Lu Z; Zhang L; Wang Z
Acta Biomater; 2022 Aug; 148():230-243. PubMed ID: 35724919
[TBL] [Abstract][Full Text] [Related]
39. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.
Santiago-Sánchez GS; Hodge JW; Fabian KP
Front Immunol; 2022; 13():993624. PubMed ID: 36159809
[TBL] [Abstract][Full Text] [Related]
40. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
